Subscribe
shutterstock_547487782_fabioberti
fabioberti / Shutterstock.com
12 February 2019Asia

Pharma group asks USTR to drop India from watch list

The lobby group for India’s pharma industry has asked the  US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.
Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.
Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.

More on this story

Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.
Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.

More features

Weight-loss clinic hits back at Novo Nordisk’s Ozempic TM allegations
Eisai and Merck shield blockbuster cancer drug from generic challenge
Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars